Current Problems in Cancer
Volume 31, Issue 3 , Pages 123-133 , May 2007

Racial Disparities in Colorectal Cancer

References 

  1. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97:1407–1427
  2. Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975-2002.
  3. Thomas CR, Jarosz R, Evans N. Racial differences in the anatomical distribution of colon cancer. Arch Surg. 1992;127(10):1241–1245
  4. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  5. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78–93
  6. Satia-Abouta J, Galanko JA, Potter JD, Ammerman A, Martin CF, Sandler RS. Associations of total energy and macronutrients with colon cancer risk in African Americans and Whites: results from the North Carolina colon cancer study. Am J Epidemiol. 2003;158:951–962
  7. Satia-Abouta J, Galanko JA, Martin CF, Ammerman A, Sandler RS. Food groups and colon cancer risk in African-Americans and Caucasians. Int J Cancer. 2004;109:728–736
  8. Butler LM, Sinha R, Millikan RC, Martin CF, Newman B, Gammon MD, et al. Heterocyclic amines, meat intake, and association with colon cancer in a population-based study. Am J Epidemiol. 2003;157:434–445
  9. Chiu HM, Lin JT, Shun CT, Liang JT, Lee YC, Huang SP, et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol. 2007;5(2):221–229
  10. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am. 2002;31:925–943
  11. Bruce WR, Giacca A, Medline A. Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev. 2000;9:1271–1279
  12. Ashktorab H, Smoot DT, Farzanmehr H, Fidelia-Lambert M, Momen B, Hylind L, et al. Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer. 2005;116:914–919
  13. Ashktorab H, Smoot DT, Carethers JM, Rahmanian M, Kittles R, Vosganian G, et al. High incidence of microsatellite instability in colorectal cancer from. Clin Cancer Res. 2003;9:1112–1117
  14. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:132–141
  15. U.S. Preventive Services Task Force. Colon cancer screening (USPSTF recommendation). J Am Geriatr Soc. 2000;48:333–335
  16. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. J Am Med Assoc. 2002;288:872–881
  17. Sansbury LB, Millikan RC, Schroeder JC, Moorman PG, North KE, Sandler RS. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol. 2005;162:548–558
  18. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276–1299
  19. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407–1427
  20. Hiatt RA, Klabunde C, Breen N, Swan J, Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst. 2002;94:1837–1846
  21. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003;97:1528–1540
  22. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and. J Natl Cancer Inst. 2001;93:501–515
  23. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. N Engl J Med. 2004;351:575–584
  24. Dayal H, Polissar L, Yang CY, Dahlberg S. Race, socioeconomic status, and other prognostic factors for survival from colo-rectal cancer. J Chronic Dis. 1987;40:857–864
  25. Mayberry RM, Coates RJ, Hill HA, Click LA, Chen VW, Austin DF, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst. 1995;87:1686–1693
  26. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002;20:1192–1202
  27. Dominitz JA, Samsa GP, Landsman P, Provenzale D. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer. 1998;82:2312–2320
  28. Dignam JJ, Ye Y, Colangelo L, Smith R, Mamounas EP, Wieand HS, et al. Prognosis after rectal cancer in blacks and whites participating in. J Clin Oncol. 2003;21:413–420
  29. Greene S, Benedetti J, Crowley J. In: Clinical Trials in Oncology. Second Edition. Boca Raton, FL: Chapman and Hall/CRC; 2003;p. 2
  30. Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999;17:3553–3559
  31. O’Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ, Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998;16:295–300
  32. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. J Am Med Assoc. 2005;294:2703–2711
  33. McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, et al. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002;94:1160–1167
  34. Ball JK, Elixhauser A. Treatment differences between blacks and whites with colorectal cancer. Med Care. 1996;34:970–984
  35. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94:334–357
  36. Alexander D, Jhala N, Chatla C, Steinhauer J, Funkhouser E, Coffey CS, et al. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer. 2005;103:2163–2170
  37. Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996;88:812–816

 Supported by grant number P60MD000525 from the National Center for Minority Health and Health Disparities and funding from the Georgia Cancer Coalition

PII: S0147-0272(07)00003-7

doi: 10.1016/j.currproblcancer.2007.01.002

Current Problems in Cancer
Volume 31, Issue 3 , Pages 123-133 , May 2007

Article Tools

* Image Usage & Resolution